Ertuğrul TAŞAN, Cumali KARATOPRAK, Adnan YAY, Servet YOLBAŞ, Mustafa ÇAKIRCA, Mehmet Ali ÇIKRIKCIOĞLU, Mehmet ZORLU, Muharrem KISKAÇ, Reha ERKOÇ

The effects of short-acting analogue insulins on body weight in patients with type 2 diabetes mellitus

To investigate the effects of short-acting analogue insulins on weight, and to demonstrate the difference between analogues. Materials and methods: Our study included patients who have used only intensive insulin therapy with metformin. Those who took other oral antidiabetics, other insulin derivatives, or different insulin combinations were excluded from the study because of the adverse effects on patients' weights. Results: Our study included 118 patients who used insulin glargine with short-acting analogue insulins, i.e. insulin aspart (38 patients), insulin lispro (28 patients), and insulin glulisine (52 patients). After 3 to 6 months of treatment, significant weight gain was observed in the patients who had used insulin aspart and insulin glulisine (P = 0.008). However, in contrast to expectations, it was found that patients who had used insulin lispro experienced weight loss. Weight change in the patient group that used insulin lispro compared with weight change in the insulin glulisine group was found to be statistically significant (P = 0.034). Conclusion: Our study showed that patients who used short-acting insulin analogues gained a little weight, patients who used insulin glulisine gained the most weight, and patients who used insulin lispro lost weight.

Anahtar Kelimeler:

Key words: Type 2 diabetes mellitus, weight gain, insulin aspart, insulin lispro, insulin glulisine

The effects of short-acting analogue insulins on body weight in patients with type 2 diabetes mellitus

Keywords:

Key words: Type 2 diabetes mellitus, weight gain, insulin aspart, insulin lispro, insulin glulisine,

PDF

___

Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes. Diabetes Care 2003; 26: 5–20.
Chan JL, Abrahamson MJ. Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin. Mayo Clin Proc 2003; 78: 459–67.
DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003; 289: 2254–64. 4. Riddle MC. The underuse of insulin therapy in North America. Diabetes Metab Res Rev 2002; 18: 42–9.
Dikmen E, Tarkun İ, Öztürk F, Arslan B, Cantürk Z. Plasma adiponectin and resistin levels in women with polycystic ovary syndrome: relation to body mass index and insulin resistance. Turk J Med Sci 2011; 41: 45–52.
Temizel M, Mert M, Bozbey C, Arman Y, Cevizci E, Altintaş N et al. Evaluation of the weight-increasing effects of biphasic analog and regular NPH insulin mixtures in patients with Type 2 diabetes mellitus. J Diabetes 2010; 2: 250–5.
Fritsche A, Larbig M, Owens D, Haring U, on behalf of the GINGER study group. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes–results of the GINGER study. Diabetes Obes Metab 2010; 12: 115–23.
Barnet PS, Braunstein GD. Diabetes mellitus. In: Andreoli TE, Benjamin IJ, Griggs RC, Wing EJ, editors. Andreoli and Carpenter’s Cecil essentials of medicine. 8th ed. Philadelphia: Saunders Elsevier; 2010. p.697–720.